Last reviewed · How we verify

GW640385 — Competitive Intelligence Brief

GW640385 (GW640385) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HIV-1 integrase inhibitor. Area: Infectious Diseases.

phase 2 HIV-1 integrase inhibitor HIV-1 integrase Infectious Diseases Small molecule Live · refreshed every 30 min

Target snapshot

GW640385 (GW640385) — ViiV Healthcare. GW640385 is a HIV-1 integrase inhibitor.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
GW640385 TARGET GW640385 ViiV Healthcare phase 2 HIV-1 integrase inhibitor HIV-1 integrase
Tenofovir Disoproxil, Lamuvidine and Dolutegravir Tenofovir Disoproxil, Lamuvidine and Dolutegravir Africa Health Research Institute phase 3 NRTI/INST HIV-1 reverse transcriptase, HIV-1 integrase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HIV-1 integrase inhibitor class)

  1. ViiV Healthcare · 3 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GW640385 — Competitive Intelligence Brief. https://druglandscape.com/ci/gw640385. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: